162 related articles for article (PubMed ID: 9632624)
1. Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines.
Becker SI; Wang R; Hedstrom RC; Aguiar JC; Jones TR; Hoffman SL; Gardner MJ
Infect Immun; 1998 Jul; 66(7):3457-61. PubMed ID: 9632624
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
Rénia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
[TBL] [Abstract][Full Text] [Related]
3. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.
Tian JH; Kumar S; Kaslow DC; Miller LH
Infect Immun; 1997 Aug; 65(8):3032-6. PubMed ID: 9234750
[TBL] [Abstract][Full Text] [Related]
4. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.
Ling IT; Ogun SA; Momin P; Richards RL; Garçon N; Cohen J; Ballou WR; Holder AA
Vaccine; 1997 Oct; 15(14):1562-7. PubMed ID: 9330469
[TBL] [Abstract][Full Text] [Related]
5. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.
Daly TM; Long CA
Infect Immun; 1996 Jul; 64(7):2602-8. PubMed ID: 8698485
[TBL] [Abstract][Full Text] [Related]
6. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.
Kedzierski L; Black CG; Coppel RL
Infect Immun; 2000 Oct; 68(10):6034-7. PubMed ID: 10992516
[TBL] [Abstract][Full Text] [Related]
7. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.
Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL
Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
Matsumoto S; Yukitake H; Kanbara H; Yamada T
J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
[TBL] [Abstract][Full Text] [Related]
9. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
Shi Q; Lynch MM; Romero M; Burns JM
Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
[TBL] [Abstract][Full Text] [Related]
10. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
Wang L; Goschnick MW; Coppel RL
Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
[TBL] [Abstract][Full Text] [Related]
11. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.
Charoenvit Y; Majam VF; Corradin G; Sacci JB; Wang R; Doolan DL; Jones TR; Abot E; Patarroyo ME; Guzman F; Hoffman SL
Infect Immun; 1999 Nov; 67(11):5604-14. PubMed ID: 10531206
[TBL] [Abstract][Full Text] [Related]
12. Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine.
Wang R; Charoenvit Y; Daly TM; Long CA; Corradin G; Hoffman SL
Immunol Lett; 1996 Nov; 53(2-3):83-93. PubMed ID: 9024983
[TBL] [Abstract][Full Text] [Related]
13. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations.
Sedegah M; Brice GT; Rogers WO; Doolan DL; Charoenvit Y; Jones TR; Majam VF; Belmonte A; Lu M; Belmonte M; Carucci DJ; Hoffman SL
Infect Immun; 2002 Jul; 70(7):3493-9. PubMed ID: 12065488
[TBL] [Abstract][Full Text] [Related]
14. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.
Sedegah M; Jones TR; Kaur M; Hedstrom R; Hobart P; Tine JA; Hoffman SL
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7648-53. PubMed ID: 9636204
[TBL] [Abstract][Full Text] [Related]
15. Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria.
Tian JH; Good MF; Hirunpetcharat C; Kumar S; Ling IT; Jackson D; Cooper J; Lukszo J; Coligan J; Ahlers J; Saul A; Berzofsky JA; Holder AA; Miller LH; Kaslow DC
Parasite Immunol; 1998 Jun; 20(6):263-78. PubMed ID: 9651928
[TBL] [Abstract][Full Text] [Related]
16. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.
Wang R; Charoenvit Y; Corradin G; De La Vega P; Franke ED; Hoffman SL
J Immunol; 1996 Nov; 157(9):4061-7. PubMed ID: 8892640
[TBL] [Abstract][Full Text] [Related]
17. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
Petritus PM; Burns JM
J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
[TBL] [Abstract][Full Text] [Related]
18. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.
Kedzierski L; Black CG; Goschnick MW; Stowers AW; Coppel RL
Infect Immun; 2002 Dec; 70(12):6606-13. PubMed ID: 12438332
[TBL] [Abstract][Full Text] [Related]
19. Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant.
De Souza JB; Ling IT; Ogun SA; Holder AA; Playfair JH
Infect Immun; 1996 Sep; 64(9):3532-6. PubMed ID: 8751895
[TBL] [Abstract][Full Text] [Related]
20. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus.
Sedegah M; Weiss W; Sacci JB; Charoenvit Y; Hedstrom R; Gowda K; Majam VF; Tine J; Kumar S; Hobart P; Hoffman SL
J Immunol; 2000 Jun; 164(11):5905-12. PubMed ID: 10820272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
